News
Nov. 18, 2020

GNS561’s successful phase 1b trial completed

Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
News
July 22, 2020

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
News
18 June, 2020

Our COVID-19 research Project supported by the French Government

Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
News
April 6, 2020

COVID-19, GNS561’s Assault begins in France !

Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
News
January 13, 2020

ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology

Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
News
December 16, 2019

GNS561 to treat pancreas or colorectal cancer with liver metastasis

GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
News
November 14, 2019

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
News
September 25, 2019

Invest in the Future of Health Biotech, European Biotech Week

Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels)  …
Read More
News
June 3, 2019

S.A.B Meeting in Chicago, during ASCO 2019

Scientific Advisory Board Meeting during ASCO 2019   Chicago, USA, June 3, 2019 — Genoscience…
Read More
News
April 17, 2019

Chaim Hurvitz, New Board of Directors Member

Chaim Hurvitz, New Board of Directors Member   Chaim Hurvitz has joined  Genoscience Pharma Board…
Read More
News
December 10, 2018

Most Innovative European Biotech SME for 2018

Most Innovative European Biotech SME for 2018   Bruxelles, Belgium, December 3, 2018 - Company…
Read More
News
October 5, 2018

Extension to US of GNS561 Clinical Trial

Genoscience Pharma Extends to US its Clinical Trial in Patients with Advanced Liver Cancers  …
Read More
News
June 4, 2018

S.A.B. Meeting in Chicago, during ASCO 2018

Scientific Advisory Board Meeting during ASCO 2018   Chicago, USA, June 4, 2018 — During…
Read More
News
May 22, 2018

Extension to France of GN561 Clinical trial

Genoscience Pharma Extends its GNS561 Clinical Trial to France   Enrollment is open for patients…
Read More
News
April 5, 2018

First-in-human Dosing of GNS561 in Liver Cancer Patients

First-in-human Dosing of GNS561 in Patients with Advanced Liver Cancer at the Jules Bordet Institute,…
Read More
News
December 6, 2017

GNS561 Gets US FDA IND Approval in Liver Cancer

Genoscience Pharma Receives FDA Approval for Phase Ib/IIa Study of GNS561 in Liver Cancer  …
Read More
News
February 24, 2016

Four New Members in Our Directory Board

Four New Members in Our Directory Board   Marseille, France, February 24, 2016 – Genoscience Pharma…
Read More
News
February 6, 2012

BL-8030 worldwide License Agreement with BioLineRx

RFS Pharma and Genoscience Pharma enter Worldwide License Agreement with BioLineRx to develop and commercialize Hepatitis…
Read More
News
January 24, 2012

BL-8020 exclusive License Agreement with BioLineRx

BioLineRx signs exclusive License Agreement for BL-8020, an oral Hepatitis C treatment   Jerusalem, Israel,…
Read More
News
June 19, 2007

Joint Venture Agreement with RFS Pharma

RFS Pharma and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors…
Read More